metformin and olanzapine

metformin has been researched along with olanzapine in 32 studies

Research

Studies (32)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (31.25)29.6817
2010's14 (43.75)24.3611
2020's8 (25.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y1
Arapé, Y; Baptista, T; Beaulieu, S; de Mendoza, S; Hernández, L; Lacruz, A; Martínez, J; Martinez, M; Rangel, N; Serrano, A; Teneud, L1
Baptista, T; Beaulieu, S; Contreras, Q; de Mendoza, S; Galeazzi, T; Lacruz, A; Rangel, N; Sandia, I; Vargas, D1
Baptista, T; Beaulieu, S; Carrizo, E; Connell, L; Dávila, A; de Baptista, EA; El Fakih, Y; Fernández, V; Galeazzi, T; Gutiérrez, MA; Rangel, N; Serrano, A; Servigna, M; Uzcátegui, E; Uzcátegui, M1
Chen, CH; Chiu, CC; Huang, MC; Liu, HC; Lu, ML; Wu, TH1
Chen, JD; Fang, MS; Guo, WB; Guo, XF; He, YQ; Li, LH; Wu, RR; Zhao, JP1
Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E1
Alamiri, B1
Balf, G1
Khaodhiar, L; Pramyothin, P1
Goyal, N; Jana, AK; Praharaj, SK; Sinha, VK1
Halatsch, ME; Karpel-Massler, G; Kast, RE1
Case, M; Hoffmann, VP; Jacobson, JG1
Barr, AM; Boyda, HN; Hawkes, E; Honer, WG; Jin, CH; Pang, CC; Procyshyn, RM; Tse, L1
Asiri, Y; Barr, AM; Boyda, HN; Honer, WG; Lo, R; Pang, CC; Procyshyn, RM; Wang, CK; Wu, C1
Davies, GE; Davies, PS; Droke, EA; Ehli, EA; Hu, Y; Nowotny, D; Soundy, TJ; Young, AJ1
Ahsan, Z; Chintoh, A; Giacca, A; Guenette, M; Hahn, MK; Remington, GJ; Teo, C; Wilson, V1
Rado, J; von Ammon Cavanaugh, S1
Nurchi, AM; Pinna, AP; Podda, F; Ripoli, C; Tronci, MG; Zanni, R1
Bansal, Y; Bishnoi, M; Kondepudi, KK; Kuhad, A; Medhi, B; Singh, DP; Singh, R; Sodhi, RK1
Bansal, Y; Bishnoi, M; Khare, P; Kondepudi, KK; Kuhad, A; Medhi, B; Singh, R; Sodhi, RK1
Huang, HX; Liu, ZQ; Luo, C; Mao, XY; Wang, X; Zhou, HH1
Guo, C; Li, H; Liu, J1
Dai, W; Ding, C; Huang, P; Huang, X; Lian, P; Ran, J; Tang, Y; Zhu, W1
Choi, SY; Jang, S; Kim, DG; Kim, J; Kim, S; Lee, CH; Lee, KW; Lee, N; Park, JK; Suh, SB1
Hahn, MK; Jeromson, S; McKie, GL; Medak, KD; Shamshoum, H; Wright, DC1

Reviews

3 review(s) available for metformin and olanzapine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Metabolic syndrome with the atypical antipsychotics.
    Current opinion in endocrinology, diabetes, and obesity, 2010, Volume: 17, Issue:5

    Topics: Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Clozapine; Humans; Metabolic Syndrome; Metformin; Obesity; Olanzapine; Practice Guidelines as Topic; Psychotic Disorders; Severity of Illness Index; Weight Gain

2010
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.
    British journal of clinical pharmacology, 2011, Volume: 71, Issue:3

    Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass Index; Humans; Hypoglycemic Agents; Metformin; Olanzapine; Overweight; Randomized Controlled Trials as Topic; Schizophrenia; Weight Gain

2011

Trials

8 trial(s) available for metformin and olanzapine

ArticleYear
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2006, Volume: 51, Issue:3

    Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypercholesterolemia; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Obesity; Olanzapine; Schizophrenia; Weight Gain

2006
Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.
    International clinical psychopharmacology, 2007, Volume: 22, Issue:2

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; C-Reactive Protein; Double-Blind Method; Female; Fibrinogen; Glucagon; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Male; Metabolic Syndrome; Metformin; Middle Aged; Olanzapine; Schizophrenia; Sex Factors; Treatment Outcome; Tumor Necrosis Factor-alpha

2007
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.
    Schizophrenia research, 2007, Volume: 93, Issue:1-3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass Index; Body Weight; Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Energy Metabolism; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipids; Male; Metformin; Middle Aged; Olanzapine; Schizophrenia; Statistics as Topic

2007
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, May-15, Volume: 32, Issue:4

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Female; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Lipids; Male; Metabolic Diseases; Metabolic Syndrome; Metformin; Middle Aged; Olanzapine; Prospective Studies; Schizophrenia; Sex Characteristics

2008
Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
    The American journal of psychiatry, 2008, Volume: 165, Issue:3

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Olanzapine; Placebos; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome; Waist-Hip Ratio; Weight Gain

2008
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
    Psychiatry research, 2008, May-30, Volume: 159, Issue:1-2

    Topics: Adult; Antipsychotic Agents; Appetite Depressants; Benzodiazepines; Body Mass Index; Chronic Disease; Cyclobutanes; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Middle Aged; Obesity; Olanzapine; Pilot Projects; Placebos; Schizophrenia; Schizophrenic Psychology; Waist-Hip Ratio; Weight Gain; Weight Loss

2008
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.
    The Journal of clinical psychiatry, 2012, Volume: 73, Issue:2

    Topics: Adolescent; Adult; Aged; Algorithms; Amantadine; Antipsychotic Agents; Benzodiazepines; Clinical Protocols; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Isoxazoles; Male; Metformin; Middle Aged; Olanzapine; Psychotic Disorders; Schizophrenia; Weight Gain; Zonisamide

2012
A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population.
    Journal of clinical psychopharmacology, 2016, Volume: 36, Issue:2

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Independent Living; Male; Mental Disorders; Metformin; Middle Aged; Olanzapine; Pilot Projects; Population Surveillance; United States; Weight Gain; Young Adult

2016

Other Studies

21 other study(ies) available for metformin and olanzapine

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Nature, 2020, Volume: 583, Issue:7816

    Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins

2020
Considerations regarding the use of metformin with olanzapine.
    The American journal of psychiatry, 2008, Volume: 165, Issue:9

    Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 2; Drug Administration Schedule; Humans; Hypoglycemic Agents; Metformin; Obesity; Olanzapine; Schizophrenia; Weight Loss

2008
Olanzapine treatment and weight gain: considering the lipid side effects of antipsychotics.
    The American journal of psychiatry, 2008, Volume: 165, Issue:9

    Topics: Antipsychotic Agents; Asian People; Benzodiazepines; Energy Intake; Exercise; Humans; Hypoglycemic Agents; Life Style; Metformin; Obesity; Olanzapine; Schizophrenia; Triglycerides

2008
Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?
    British journal of pharmacology, 2011, Volume: 164, Issue:5

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Benzodiazepines; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Energy Metabolism; Enzyme Activation; Glioblastoma; Humans; Metformin; Olanzapine; Temozolomide

2011
Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.
    Journal of psychiatry & neuroscience : JPN, 2012, Volume: 37, Issue:6

    Topics: Animals; Antipsychotic Agents; Benzodiazepines; Female; Glucose Intolerance; Glyburide; Hypoglycemic Agents; Insulin Resistance; Metformin; Olanzapine; Rats; Rosiglitazone; Thiazolidinediones

2012
Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine.
    Progress in neuro-psychopharmacology & biological psychiatry, 2014, Jan-03, Volume: 48

    Topics: Animals; Benzodiazepines; Disease Models, Animal; Drug Therapy, Combination; Fasting; Female; Glucose Intolerance; Glucose Tolerance Test; Glyburide; Hypoglycemic Agents; Insulin; Metformin; Olanzapine; Rats; Rats, Sprague-Dawley; Rosiglitazone; Selective Serotonin Reuptake Inhibitors; Thiazolidinediones; Time Factors

2014
Metformin and berberine prevent olanzapine-induced weight gain in rats.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Adipose Tissue, White; Animals; Antipyretics; Benzodiazepines; Berberine; Eating; Female; Ion Channels; Metformin; Mitochondrial Proteins; Olanzapine; Organ Size; Rats; Rats, Sprague-Dawley; Transcriptome; Uncoupling Protein 1; Weight Gain

2014
Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance.
    The Journal of endocrinology, 2015, Volume: 227, Issue:2

    Topics: Animals; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Glucose Clamp Technique; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metformin; Olanzapine; Rats; Rats, Sprague-Dawley

2015
Second-generation antipsychotic and diabetes mellitus in children and adolescents.
    La Pediatria medica e chirurgica : Medical and surgical pediatrics, 2017, Dec-13, Volume: 39, Issue:4

    Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Benzodiazepines; Blood Glucose; Clomipramine; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; Lithium; Male; Metformin; Olanzapine; Valproic Acid

2017
Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels.
    Life sciences, 2020, Apr-15, Volume: 247

    Topics: Animals; Antipsychotic Agents; Berberine; Body Temperature; Body Weight; Cytokines; Drinking; Female; Gene Expression Regulation; Ghrelin; Hypothalamus; Leptin; Metabolic Diseases; Metformin; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Neuropeptides; Obesity; Olanzapine; RNA, Messenger; Signal Transduction; Treatment Outcome; TRPV Cation Channels

2020
Role of TRPV1/TRPV3 channels in olanzapine-induced metabolic alteration: Possible involvement in hypothalamic energy-sensing, appetite regulation, inflammation and mesolimbic pathway.
    Toxicology and applied pharmacology, 2020, 09-01, Volume: 402

    Topics: Animals; Appetite Regulation; Capsaicin; Coloring Agents; Energy Metabolism; Female; Furans; Gene Expression Regulation; Glucose Tolerance Test; Hypoglycemic Agents; Hypothalamus; Inflammation; Metformin; Mice; Mice, Inbred BALB C; Motor Activity; Olanzapine; Ruthenium Red; Sensory System Agents; TRPV Cation Channels

2020
Coadministration of metformin prevents olanzapine-induced metabolic dysfunction and regulates the gut-liver axis in rats.
    Psychopharmacology, 2021, Volume: 238, Issue:1

    Topics: Adjuvants, Pharmaceutic; Animals; Bacteroides; Blood Glucose; Body Weight; Dose-Response Relationship, Drug; Feces; Gastrointestinal Microbiome; Humans; Lactobacillus gasseri; Liver; Male; Metabolic Diseases; Metformin; Olanzapine; Rats; RNA, Ribosomal, 16S

2021
Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 133

    Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents; Blood Glucose; Cytokines; Disease Models, Animal; Epididymis; Hypoglycemic Agents; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Macrophages; Male; Metformin; Olanzapine; Phenotype; Rats, Sprague-Dawley; Signal Transduction; Weight Gain

2021
Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway.
    Scientific reports, 2022, 04-04, Volume: 12, Issue:1

    Topics: Animals; Liver X Receptors; Metformin; Mice; Non-alcoholic Fatty Liver Disease; Olanzapine; Proprotein Convertase 9

2022
Metformin ameliorates olanzapine-induced disturbances in POMC neuron number, axonal projection, and hypothalamic leptin resistance.
    BMB reports, 2022, Volume: 55, Issue:6

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Female; Hypothalamus; Leptin; Metformin; Mice; Neurons; Obesity; Olanzapine; Pro-Opiomelanocortin

2022
Salsalate and/or metformin therapy confer beneficial metabolic effects in olanzapine treated female mice.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 168

    Topics: Animals; Antipsychotic Agents; Benzodiazepines; Female; Glucose; Humans; Lipids; Metformin; Mice; Olanzapine; Salicylates; Weight Gain

2023